EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan

Arshad Hussain, Muhammad Umar Wahab, Saleem Qureshi, Umar Yousaf Raja, Atif Munir, Shahnawaz Gardezi, Musarrat Iqbal, Bilal Afzal, Muhammad Daoud Butt, Siew Chin Ong iD

Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8438-8451

DOI: 10.1111/dom.71043 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.06.2026. Verfasst von Arshad Hussain und 9 weiteren Autor:innen. Beteiligte Einrichtung: North-West General Hospital, Peshawar, Pakistan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BF Bioscience Pvt. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the real‐world effectiveness, safety and patient‐reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes mellitus (T2DM) receiving routine outpatient care in a cost‐constrained setting.

Methods

This 30‐week, prospective, multicentre, non‐interventional study enrolled adults with T2DM initiating biosynthetic semaglutide. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to end of study (EOS). Secondary endpoints included changes in body weight, waist circumference, patient‐reported outcomes (DTSQs and SF‐36v2) and safety.

Results

Among 217 patients, mean HbA1c decreased from 9.27% to 7.41% at EOS (−1.86%; p < 0.001). At EOS, 76.6% achieved HbA1c < 8.0% and 38.7% achieved < 7.0%. Mean body weight decreased by −7.84 kg ( p < 0.001), with 76.5% achieving ≥ 5% weight loss. Significant reductions were also observed in body mass index and waist circumference. Treatment satisfaction and physical quality of life improved significantly. Adverse events were predominantly non‐serious and gastrointestinal. No severe hypoglycaemic episodes occurred.

Conclusions

In routine clinical practice, biosynthetic semaglutide was associated with clinically meaningful improvements in glycaemic control, body weight and physical quality of life. The safety profile remained consistent with established semaglutide therapy. Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12625000610437

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsHumansSemaglutideFemaleMaleMiddle AgedGlycated HemoglobinProspective StudiesPakistanTreatment OutcomeAdultWeight LossAgedQuality of LifeBody Mass IndexWaist CircumferencePatient Reported Outcome MeasuresBlood Glucose

Stichwörter der Autor:innen

biosynthetic semaglutideglycaemic controllow‐ and middle‐income countriespatient‐reported outcomesreal‐world evidencesafety and tolerability

Substanzen

SemaglutideGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic Agentshemoglobin A1c protein, humanBlood Glucose

Autor:innen und Institutionen

  • North-West General Hospital, Peshawar, Pakistan.
  • Umar Diabetes and Foot Care Centre and Umar Diabetes Foundation, Islamabad, Pakistan.
  • Department of Medicine, Center for Diabetes and Liver Disease, Islamabad, Pakistan.
  • Shifa International Hospitals Ltd., Islamabad, Pakistan.
  • Omer Hospital, Lahore, Pakistan.
  • City Hospital, Multan, Pakistan.

ORCID-Profile: Siew Chin Ong

Förderung

  • BF Bioscience Pvt. Ltd.

Zitieren

APA

Hussain, A., Wahab, M. U., Qureshi, S., Raja, U. Y., Munir, A., Gardezi, S., Iqbal, M., Afzal, B., Butt, M. D., & Ong, S. C. (2026). Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. Diabetes, Obesity and Metabolism, 28(9), 8438-8451. https://doi.org/10.1111/dom.71043

Vancouver

Hussain A, Wahab MU, Qureshi S, Raja UY, Munir A, Gardezi S, et al. Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan. Diabetes, Obesity and Metabolism. 2026;28(9):8438-8451. doi:10.1111/dom.71043

BibTeX
@article{Hussain2026,
  author = {Hussain, Arshad and Wahab, Muhammad Umar and Qureshi, Saleem and Raja, Umar Yousaf and Munir, Atif and Gardezi, Shahnawaz and Iqbal, Musarrat and Afzal, Bilal and Butt, Muhammad Daoud and Ong, Siew Chin},
  title = {Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {9},
  pages = {8438--8451},
  doi = {10.1111/dom.71043}
}
Kostenlos starten →